NCEL · NewcelX Ltd.

NewcelX’s 2025 financial results reflect continued heavy investment in its lead program, NCEL-101, with net loss of $8.3 million — though $5.7 million of that was non-cash, tied to fair value remeasurement of derivative liabilities from pre-merger convertible instruments and explicitly noted as non-recurring. Operating cash use of $2.8 million aligns with disclosed acceleration in manufacturing prep, regulatory planning, and merger-related obligations. The $2.2 million cash balance at year-end — up from $650,000 in 2024 — reflects both prior-year fundraising and the April 2026 $1.35 million private placement (plus $2.0 million potential warrant proceeds), which strengthens near-term liquidity without adding debt. Management frames 2026 as a year of 'significantly accelerated execution', targeting key IND-enabling milestones for NCEL-101, leveraging validated platform capabilities from AstroRx® and DOXA programs, and pursuing non-dilutive partnerships. The appointment of Dr. Julien Boisdron to the Scientific Advisory Board signals intensified focus on translational diabetes expertise. While the company remains pre-revenue and unprofitable, its clean balance sheet, scalable hPSC platform, and strategic collaboration with Eledon Pharmaceuticals position it to advance toward clinical-stage validation — a critical inflection point for investor assessment of functional cure potential in Type 1 Diabetes.